Decoding Colorectal Cancer: Innovations in Biomarkers, Microbiota, and Therapeutic Resistance
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 85
Special Issue Editor
2. Department of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine, College of Design and Engineering, National University of Singapore, Singapore 119074, Singapore
3. Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore
Interests: colorectal cancer; biomarkers; microbiota; nanomaterials
Special Issue Information
Dear Colleagues,
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, necessitating continuous advancements in its prevention, diagnosis, and treatment. In recent years, a deeper understanding of CRC pathogenesis has revealed complex molecular signatures, tumor microenvironmental interactions, and host–microbiota dynamics that contribute to disease progression and therapeutic resistance. Notably, innovations in biomarker discovery—from circulating tumor DNA and exosomal RNAs to metabolic and microbial signatures—are reshaping early detection and paving the way for personalized therapeutic strategies.
This Special Issue, “Decoding Colorectal Cancer: Innovations in Biomarkers, Microbiota, and Therapeutic Resistance”, aims to showcase cutting-edge research that deciphers the biological complexity of CRC. We welcome studies investigating the interplay between tumor genomics, gut microbiota, and resistance to chemotherapy, targeted therapy, and immunotherapy. Contributions utilizing emerging technologies such as multi-omics integration, organoid models, AI-driven radiomics, and spatial transcriptomics are particularly encouraged.
Biomarkers play a critical role in the tumorigenesis, progression, recurrence, and metastasis of colorectal cancer. Their clinical detection facilitates individualized treatment planning, offering the potential to improve therapeutic outcomes and survival rates. With the continued advancement of genomics and molecular biology, numerous biomarkers have been translated into clinical practice, underscoring the need for further clinical studies to validate their utility and expand their application.
Moreover, nanomaterials have demonstrated tremendous promise in oncology by enhancing drug delivery efficiency, minimizing systemic toxicity, and overcoming treatment resistance. As novel nanomaterials and scalable production technologies evolve, CRC therapies are expected to become increasingly precise and effective. Research into the application of nanomedicine in colorectal cancer is therefore poised to become a major driver of innovation in this field.
We invite original research articles, comprehensive reviews, pre-clinical research, and methodologically rigorous perspectives that expand our understanding of colorectal cancer and contribute to the advancement of precision oncology.
Dr. Yinghao Cao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- tumor biomarkers
- nanomaterials
- drug delivery
- microbiome–tumor interaction
- therapeutic resistance
- exosomes
- tumor microenvironment
- prognostic model
- neoadjuvant therapy
- conversion therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
